{"id":"placebo-for-isoniazid-inh","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of active drugs by comparison. Any observed effects in placebo groups are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. In this case, it serves as a control comparator in isoniazid (INH) studies for tuberculosis.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:55.502Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in isoniazid efficacy and safety trials for tuberculosis"}]},"trialDetails":[{"nctId":"NCT04951986","phase":"PHASE3","title":"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2021-08-11","conditions":"Disseminated Tuberculosis, HIV","enrollment":732},{"nctId":"NCT05473520","phase":"PHASE3","title":"Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-05-24","conditions":"Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)","enrollment":150},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT07118696","phase":"PHASE3","title":"Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2026-02-01","conditions":"Pulmonary TB","enrollment":1000},{"nctId":"NCT06676800","phase":"EARLY_PHASE1","title":"Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Fourth Affiliated Hospital of Xinjiang Medical University","startDate":"2024-11-30","conditions":"Tuberculosis-related Obstructive Pulmonary Disease","enrollment":74},{"nctId":"NCT06618573","phase":"PHASE2, PHASE3","title":"Safety of Administering Isoniazid to SLE Patients to Prevent TB","status":"RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2022-08-15","conditions":"Tuberculosis, Systemic Lupus Erythematosus","enrollment":60},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT04600167","phase":"PHASE3","title":"Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","status":"UNKNOWN","sponsor":"Dr. Nyanda Elias Ntinginya","startDate":"2022-06-17","conditions":"Diabetes Mellitus, Tuberculosis","enrollment":3000},{"nctId":"NCT05215990","phase":"PHASE1, PHASE2","title":"Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-01-15","conditions":"Tuberculosis, Pulmonary","enrollment":80},{"nctId":"NCT01494038","phase":"PHASE4","title":"Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-08-19","conditions":"HIV Infections, Tuberculosis","enrollment":956},{"nctId":"NCT04499976","phase":"PHASE4","title":"Isonicotinic Acid Hydrazide Pretreatment With Misoprostol Induction of Abortion in First-trimester Missed Miscarriage","status":"UNKNOWN","sponsor":"Aswan University Hospital","startDate":"2020-09-01","conditions":"Abortion, Missed","enrollment":240},{"nctId":"NCT03028129","phase":"PHASE4","title":"Prevention of Tuberculosis in Prisons","status":"TERMINATED","sponsor":"Federal University of Mato Grosso","startDate":"2017-09-04","conditions":"Tuberculosis, Pulmonary, Antibiotic Prophylaxis","enrollment":467},{"nctId":"NCT00330304","phase":"PHASE3","title":"Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2003-01","conditions":"Tuberculosis","enrollment":450},{"nctId":"NCT00080119","phase":"PHASE2, PHASE3","title":"Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2004-02","conditions":"HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia","enrollment":1354},{"nctId":"NCT02774993","phase":"PHASE2","title":"Doxycycline in Human Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2015-09","conditions":"Tuberculosis","enrollment":40},{"nctId":"NCT01408914","phase":"PHASE2","title":"Trial of High-Dose Rifampin in Patients With TB","status":"COMPLETED","sponsor":"Harvard University Faculty of Medicine","startDate":"2013-09","conditions":"Tuberculosis","enrollment":180},{"nctId":"NCT00864383","phase":"PHASE3","title":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2008-01","conditions":"Pulmonary Tuberculosis","enrollment":1931},{"nctId":"NCT01215851","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-10","conditions":"Pulmonary Tuberculosis","enrollment":85},{"nctId":"NCT02313610","phase":"PHASE2","title":"Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-04","conditions":"Pulmonary Tuberculosis","enrollment":253},{"nctId":"NCT01287221","phase":"PHASE3","title":"Study of Rifampicin in Multiple System Atrophy","status":"TERMINATED","sponsor":"Phillip Low","startDate":"2011-03","conditions":"Multiple System Atrophy","enrollment":100},{"nctId":"NCT00164281","phase":"PHASE4","title":"Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-11","conditions":"Tuberculosis, HIV Infections","enrollment":2000},{"nctId":"NCT00463086","phase":"NA","title":"Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2007-11","conditions":"Tuberculosis, Latent Tuberculosis Infection, HIV Infections","enrollment":1368},{"nctId":"NCT00633256","phase":"NA","title":"The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-12","conditions":"Smoking","enrollment":20},{"nctId":"NCT00144417","phase":"PHASE2","title":"TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2006-02","conditions":"Tuberculosis","enrollment":433},{"nctId":"NCT00130325","phase":"NA","title":"A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2004-10","conditions":"Tuberculosis","enrollment":214},{"nctId":"NCT00513396","phase":"PHASE2, PHASE3","title":"High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis","status":"COMPLETED","sponsor":"GSVM Medical College","startDate":"2004-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for isoniazid (INH)","genericName":"Placebo for isoniazid (INH)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in isoniazid efficacy and safety trials for tuberculosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}